CooperSurgical

CT - TrumbullBiotechnology1 H-1B visas (FY2023)

Focus: CooperSurgical is a women's health and medical devices company headquartered in Trumbull, CT, specializing in contraception, fertility, and gynecological products. The company operates as a biotechnology firm with a portfolio of branded and generic pharmaceuticals alongside device-based solutions.

Women's Health

Profile data last refreshed 6h ago · AI intelligence enriched 3w ago

Open Jobs

About CooperSurgical

AI assessmentNot Hiring

No open roles listed right now. Follow CooperSurgical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthWatch

Pipeline

Early-stage

5 total

LOE Risk

2 imminent

ALSUMA

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

IDKIT:HP

Not specified

LOE Approaching

Diagnostic NDA approaching loss of exclusivity; represents patent cliff exposure.

Help build intelligence for CooperSurgical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Strong foothold in women's health, a growing and underserved therapeutic area with significant unmet clinical needs
Portfolio includes both pharmaceutical NDAs and innovative devices (e.g., Paragard T380A, Her Option Cryotherapy), offering cross-functional career exposure
Active phase 4 pipeline in contraception and menorrhagia, signaling ongoing commercialization and real-world evidence generation

Watch Out For

Multiple products approaching LOE (PARAGARD T380A LOE 2027-06, ALSUMA LOE 2027-08), raising patent cliff risk and potential restructuring pressure within 2–3 years
Zero active job postings at time of data collection; minimal hiring signals and limited H1B sponsorship (1 approval, 0 denials in 2023) suggest tight or stable headcount

Generated by Claude from CooperSurgical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.